Overview

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).

Phase:

Phase 3

Details

Lead Sponsor:

GW Pharmaceuticals Ltd.

Treatments:

Dronabinol
Nabiximols